Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Modulation of LMNA splicing as a strategy to treat prelamin A diseases
John M. Lee, … , Stephen G. Young, Loren G. Fong
John M. Lee, … , Stephen G. Young, Loren G. Fong
Published March 21, 2016
Citation Information: J Clin Invest. 2016;126(4):1592-1602. https://doi.org/10.1172/JCI85908.
View: Text | PDF
Research Article Aging

Modulation of LMNA splicing as a strategy to treat prelamin A diseases

  • Text
  • PDF
Abstract

The alternatively spliced products of LMNA, lamin C and prelamin A (the precursor to lamin A), are produced in similar amounts in most tissues and have largely redundant functions. This redundancy suggests that diseases, such as Hutchinson-Gilford progeria syndrome (HGPS), that are caused by prelamin A–specific mutations could be treated by shifting the output of LMNA more toward lamin C. Here, we investigated mechanisms that regulate LMNA mRNA alternative splicing and assessed the feasibility of reducing prelamin A expression in vivo. We identified an exon 11 antisense oligonucleotide (ASO) that increased lamin C production at the expense of prelamin A when transfected into mouse and human fibroblasts. The same ASO also reduced the expression of progerin, the mutant prelamin A protein in HGPS, in fibroblasts derived from patients with HGPS. Mechanistic studies revealed that the exon 11 sequences contain binding sites for serine/arginine-rich splicing factor 2 (SRSF2), and SRSF2 knockdown lowered lamin A production in cells and in murine tissues. Moreover, administration of the exon 11 ASO reduced lamin A expression in wild-type mice and progerin expression in an HGPS mouse model. Together, these studies identify ASO-mediated reduction of prelamin A as a potential strategy to treat prelamin A–specific diseases.

Authors

John M. Lee, Chika Nobumori, Yiping Tu, Catherine Choi, Shao H. Yang, Hea-Jin Jung, Timothy A. Vickers, Frank Rigo, C. Frank Bennett, Stephen G. Young, Loren G. Fong

×

Figure 2

ASOs modulate LMNA expression.

Options: View larger image (or click on image) Download as PowerPoint
ASOs modulate LMNA expression.
(A) ASOs modulate LMNA alternative splici...
(A) ASOs modulate LMNA alternative splicing in human cells. Triplicate wells of wild-type human fibroblasts (clone CRL-2429) were transfected with ASO E11-26, E11-28, E11-31, E11-33, E11-36, E11-38, and E11-41. After 3 days, prelamin A and lamin C mRNA levels were measured by qRT-PCR. The data are expressed relative to cells treated with a scrambled ASO (Con) (set at a value of 1.0). The mean ± SD is shown. All yielded statistically significant differences compared with the control (P < 0.01, t test). (B) Modulating LMNA alternative splicing with ASO E11-31 in multiple cell types. Human skin fibroblasts (SKF; clone AG2492), HepG2 cells, HeLa cells, osteoblasts (OsteoB), chondrocytes (Chond), and smooth muscle cells (SMC) were transfected with ASO E11-31 or transfection reagent alone. After 2 days, prelamin A and lamin C transcript levels were measured by qRT-PCR and expressed relative to the nontemplate control (set at a value of 1.0). (C) Decreasing lamin A protein levels with ASO E11-31 in several human cell types. The same cell types described in B were transfected with ASO E11-31 or transfection reagent alone. After 3 days, the expression of lamin A and C was measured by Western blotting. Actin levels were measured as a loading control. Lamin protein expression was quantified and expressed relative to the nontemplate control (set at a value of 1.0). (D) ASO E11-31 decreases progerin levels in HGPS cells. Duplicate wells of HGPS cells were transfected once with ASO E11-31. Cells were harvested 1–5 days later, and the expression of lamin A, lamin C, and progerin was measured by Western blotting. Actin levels were measured as a loading control. The data are expressed relative to cells treated with a scrambled ASO (set at a value of 1.0).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts